Davide Carlesimo

Davide Carlesimo

Auto-generated profile, based on publicly available information

Davide Carlesimo

Dermatology Unit, Department of Clinical Internal, Anesthesiological and Cardiovascular Science, La Sapienza University of Rome, Italy

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 August 2025 in Dermatology Reports
Verified
Journal Article
Open access
PDF file
MVMarco Virone
Marco Virone
EZElena Zappia
Elena Zappia
ACAlberto Di Caro
Alberto Di Caro
DCDavide Carlesimo
Davide Carlesimo
NBNicoletta Bernardini
Nicoletta Bernardini
ADAnnunziata Dattola
Annunziata Dattola
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease characterized by painful nodules, abscesses, and draining tunnels in areas such as the axillae, groin, and inframammary regions. It typically emerges in early adulthood, with a global prevalence of approximately 1%, though regional variations exist. HS significantly affects patients’ quality of life and imposes considerable socioeconomic burdens. It is frequently associated with metabolic syndrome, inflammatory arthritis, and inflammatory bowel disease, reflecting its underlying systemic inflammatory nature. The pathogenesis of HS involves innate immune mechanisms, including macrophages, neutrophils, interleukin (IL)-1β, tumor necrosis factor (TNF)-α, and granulocyte colony-stimulating factor, alongside adaptive immune responses mediated by T cells (IL-17, interferon [IFN]-γ) and B cells, which contribute to autoantibody formation and tertiary lymphoid structures. Chronic inflammation results in irreversible tissue damage, tunnel formation, and severe scarring. Treatment strategies vary based on disease severity. Early inflammatory stages benefit from pharmacological therapies, while later stages require a combination of medical and surgical interventions, with surgery often necessary for advanced cases. The introduction of targeted biologic therapies, including TNF-α (adalimumab) and IL-17 inhibitors (secukinumab, bimekizumab), has expanded treatment options beyond traditional antibiotic regimens. Effective management focuses on early intervention to prevent irreversible damage, control symptoms such as pain, and address systemic comorbidities. A timely diagnosis, along with a multidisciplinary and personalized approach, is essential for improving patient outcomes and quality of life.